Skip to main content
Andreas Lauer, MD, Ophthalmology, Portland, OR, OHSU Hospital

AndreasKatsuyaLauerMD

Ophthalmology Portland, OR

Retinal Disease

Chair, Department of Ophthalmology

Dr. Lauer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Lauer's full profile

Already have an account?

Education & Training

  • Oregon Health & Science University
    Oregon Health & Science UniversityResidency, Ophthalmology, 1995 - 1999
  • University of Oklahoma Health Sciences Center
    University of Oklahoma Health Sciences CenterInternship, Internal Medicine, 1994 - 1995
  • University of Oklahoma College of Medicine
    University of Oklahoma College of MedicineClass of 1994
  • University of Rochester
    University of RochesterBA, Biology / French, 1984 - 1988

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2005 - 2026
  • OR State Medical License
    OR State Medical License 1999 - 2025
  • OK State Medical License
    OK State Medical License 1995 - 1996
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
  • Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Classification of Choroidal Neovascularization Using Projection-Resolved Optical Coherence Tomographic Angiography  
    J Peter Campbell, Thomas Hwang, Steven T Bailey, Christina Flaxel, Brandon Lujan, David Huang, Andreas Lauer, Lee Kiang, Investigative Ophthalmology and Visual Science

Press Mentions

  • AGTC to Present Three-Month Interim Results from the SKYLINE Clinical Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa at the 45th Macula Society Annual Meeting
    AGTC to Present Three-Month Interim Results from the SKYLINE Clinical Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa at the 45th Macula Society Annual MeetingJune 6th, 2022
  • Let’s Talk About Gene Therapy for Inherited Retinal Diseases
    Let’s Talk About Gene Therapy for Inherited Retinal DiseasesAugust 11th, 2021
  • First-Ever CRISPR Gene Editing Within the Human Body Used to Address Blindness Mutation
    First-Ever CRISPR Gene Editing Within the Human Body Used to Address Blindness MutationMarch 6th, 2020
  • Join now to see all

Professional Memberships

Hospital Affiliations